AM Study Update: March 11, 2026

Evidence Watch  |  Nature medicine (2025)

Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.

# Study Summary This phase 3 trial evaluated full-spectrum cannabis extract for chronic low back pain treatment, addressing a condition affecting over 500 million people globally where current pharmacotherapies demonstrate limited efficacy and significant safety concerns.

Evidence Watch  |  Acta paediatrica (Oslo, Norway : 1992) (2025)

Cannabinoids for Medical Purposes in Children: A Living Systematic Review.

# Study Summary This living systematic review continuously evaluates safety and efficacy data of cannabinoids for pediatric medical use, enabling clinicians to access updated evidence on cannabinoid treatment outcomes in children.

Evidence Watch  |  British journal of sports medicine (2026)

Influences on the mental health and well-being of retired professional athletes from high contact team sports: a mixed methods systematic review.

# Study Summary for Cannabis Clinicians This systematic review identifies mental health symptoms and influencing factors in retired high contact team sport athletes, potentially informing cannabis treatment considerations for this population’s psychiatric outcomes.

Evidence Watch  |  Journal of medical Internet research (2024)

Effectiveness of the Minder Mobile Mental Health and Substance Use Intervention for University Students: Randomized Controlled Trial.

# Study Finding Summary The Minder mobile intervention showed effectiveness for university students’ mental health and substance use challenges, offering cannabis clinicians a scalable digital tool model for student populations during vulnerable transition periods.

Evidence Watch  |  Journal of anxiety disorders (2024)

Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.

This meta-analysis examines whether evidence-based PTSD treatments remain effective for individuals with co-occurring cannabis use and substance use disorders, directly informing clinical treatment decisions.

Evidence Watch  |  BMJ open (2026)

Research on Eating and Adolescent Lifestyle (REAL) 2.0: 15-year follow-up study of eating disorders and weight-related trajectories, mental health and substance use health from early adolescence to early adulthood-a Canadian cohort profile.

# REAL 2.0 Study Summary for Cannabis Clinicians The abstract provided is incomplete and contains no findings. A one-sentence summary cannot be written without access to the study’s results section or conclusions.

Evidence Watch  |  Annals of the rheumatic diseases (2026)

Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.

# Study Summary **Unable to provide findings summary:** The abstract provided is incomplete and cuts off before results are presented, preventing accurate characterization of study outcomes for clinical relevance.

Evidence Watch  |  International journal of environmental research and public health (2026)

Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.

# Study Summary Cannabis flower use showed greater daily anxiety reduction than edibles, suggesting product type influences therapeutic efficacy for anxiety management in clinical populations.

Evidence Watch  |  Journal of sleep research (2026)

Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.

# Study Summary This pilot trial examined how oral cannabinoids (THC and CBD) affect sleep architecture and daytime function using high-density EEG, providing clinicians evidence-based data on cannabinoid efficacy for insomnia treatment.

Evidence Watch  |  Clinical pharmacology and therapeutics (2026)

Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.

CBD showed no direct effect on cortical excitability in this randomized controlled trial, suggesting its anti-seizure benefits in Dravet and Lennox-Gastaut syndromes may operate through mechanisms other than direct cortical modulation.

Evidence Watch  |  Journal of psychiatric research (2025)

Pre-trauma insomnia and posttraumatic alcohol and cannabis use in the AURORA observational cohort study of trauma survivors.

# Study Finding Summary Pre-trauma insomnia predicted increased posttraumatic cannabis use in trauma survivors, suggesting clinicians should assess insomnia when treating cannabis use disorder in this population.

Evidence Watch  |  JAMA health forum (2026)

Adolescent Cannabis Use and Risk of Psychotic, Bipolar, Depressive, and Anxiety Disorders.

# Study Finding Summary Adolescent cannabis use is associated with increased risk of psychotic, bipolar, depressive, and anxiety disorders, requiring clinicians to assess cannabis exposure during mental health evaluations in youth populations.

Evidence Watch  |  Drug and alcohol dependence (2016)

Anxiety, depression and risk of cannabis use: Examining the internalising pathway to use among Chilean adolescents.

# Study Summary Adolescents with internalising symptoms (depression, anxiety) may use cannabis as self-medication; clinicians should screen for and address underlying mental health conditions when treating cannabis use in this population.

Evidence Watch  |  Journal of clinical pharmacology (2025)

Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review.

# Study Summary This systematic review evaluates cannabis derivatives and analogs as potential therapeutic interventions for autism spectrum disorder, assessing clinical evidence for their efficacy in managing autism-related symptoms.

Evidence Watch  |  The Journal of clinical psychiatry (2024)

Maternal Cannabis Use in Pregnancy and Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder in Offspring.

# Study Finding Summary Maternal cannabis use during pregnancy is associated with increased risk of autism spectrum disorder or ADHD in offspring, relevant to clinicians counseling pregnant patients on cannabis safety.

Evidence Watch  |  Addictive behaviors (2026)

Working memory capacity predicts cannabis-induced effects on alcohol urge.

# Study Summary for Cannabis Clinicians Working memory capacity predicts individual differences in cannabis’s effects on alcohol craving, suggesting cognitive capacity may help identify patients at risk for altered alcohol use patterns when using cannabis.

Evidence Watch  |  Cannabis and cannabinoid research (2026)

A Randomized, Open-Label Trial to Assess Feasibility and Tolerability of Topical Cannabis Balms for the Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS).

# Study Summary This trial evaluates whether topical cannabis balms can effectively treat musculoskeletal pain in postmenopausal breast cancer patients using aromatase inhibitors, addressing a common treatment side effect affecting two-thirds of this population.

Evidence Watch  |  Psychiatry research. Neuroimaging (2026)

A single dose of cannabidiol modulates the relationship between hippocampal glutamate and learning-related prefrontal activation in individuals at Clinical High Risk of Psychosis.

# Study Finding Summary A single CBD dose modulated the relationship between hippocampal glutamate and prefrontal brain activation during learning tasks in individuals at clinical high risk for psychosis, suggesting a potential neurobiological mechanism relevant to psychosis prevention.

Evidence Watch  |  Medicine and science in sports and exercise (2026)

Daily Use of a Broad-Spectrum Cannabidiol Supplement Produces Detectable Concentrations of Cannabinoids in Urine Prohibited by the World Anti-Doping Agency: An Effect Amplified by Exercise.

# Study Finding Summary Broad-spectrum CBD supplements contain prohibited cannabinoids that accumulate in urine with daily use and exercise, potentially causing positive WADA drug tests despite CBD’s legal status.

Evidence Watch  |  Journal of neurodevelopmental disorders (2025)

Long-term safety and tolerability of transdermal cannabidiol gel in children and adolescents with Fragile X syndrome (ZYN2-CL-017): an interim analysis of an ongoing open-label extension study.

# Study Summary ZYN002, a transdermal cannabidiol gel, demonstrated long-term safety and tolerability in pediatric FXS patients, providing clinical evidence for cannabidiol’s potential therapeutic application in this genetic disorder characterized by dysregulated endocannabinoid signaling.